Testagen
A synthetic tetrapeptide (Lys-Glu-Asp-Gly) sold within the Khavinson bioregulator catalogue. PubMed indexes exactly two records mentioning it: a 2011 in-vitro study of nuclear penetration co-authored by the programme's developer, and a 2025 paper using it as a copper corrosion inhibitor. Both state the same sequence, which is the strongest thing that can be said for this compound.
Lys-Glu-Asp-Gly · 4 residues · 447.45 Da (computed)
Lysine at position 1 (terminal).
Bioregulator context
Target tissue: not established — no located primary source names a source or target tissue for this peptide (unknown)
That short synthetic peptides of this family carry tissue-specific regulatory information and act by entering the cell nucleus and binding DNA in a sequence-selective way. Testagen appears in that programme as one of several peptides used to demonstrate the nuclear-penetration and preferential-binding effect, rather than as a compound with a claimed clinical effect of its own in the indexed literature.
Proposed to penetrate the nucleus and discriminate between nucleotide sequences — the 2011 paper reports differential quenching of labelled oligonucleotides and a preference for CAG-containing sequences, and argues from that to epigenetic control of gene activity. The argument runs from a binding measurement in a cell-free system to gene regulation in an organism without anything in between.
Mechanism
Claimed
Regulates gene activity in its target tissue by entering the nucleus and binding DNA sequence-selectively.
Actually established
A fluorescein-labelled form of the peptide was observed in the cytoplasm, nucleus and nucleolus of HeLa cells, and in a cell-free system the peptide quenched labelled oligonucleotide fluorescence differently depending on nucleotide sequence and cytosine methylation. That is nuclear entry by a labelled derivative and differential binding in a tube. No gene-expression change, and no physiological outcome of any kind, has been demonstrated in any organism.
How good is the evidence
PubMed indexed exactly two records mentioning Testagen when checked on 2026-08-06. One is a 2011 Russian in-vitro study of nuclear penetration and DNA binding, co-authored by the bioregulator programme's developer, in which Testagen is one of four peptides tested. The other is a 2025 Romanian materials-chemistry paper that uses the peptide as a corrosion inhibitor on copper electrodes in saline and carries no biological information at all. There is no animal work, no human work, no pharmacokinetics, and no safety report. Two papers, one of them about metal, is not a thin evidence base — it is close to no evidence base.
Of the two indexed papers, the biological one lists the programme's developer as an author and the independent one has no biological interest in the compound. There is therefore no independent biological work on this substance whatsoever, and nothing to replicate.
Claims, one at a time
Each claim carries its own evidence tier. A compound is never simply "well studied" — some of its claims may be, others not at all.
| Claim | Verdict | Evidence | Basis |
|---|---|---|---|
| Enters the cell nucleus and binds DNA sequence-selectively | supported | In vitro | One paper reports marked fluorescence in the cytoplasm, nucleus and nucleolus of HeLa cells after incubation, and sequence-dependent Stern-Volmer quenching constants against labelled deoxyribooligonucleotides, with Testagen reported to prefer CAG-containing sequences. Supported at tier E and no further: the peptide tracked was chemically modified with a fluorescein label, the binding work is cell-free, the compound's developer is an author, and no consequence of the binding — on transcription or anything else — was measured. |
| Supports testicular function and male hormonal health | untested | Anecdote | No study in any species has measured a reproductive, hormonal, or ageing endpoint for this compound — the indexed literature consists of one cell-binding paper and one corrosion-inhibition paper. This claim is recorded because it is what the compound's name and its position in the bioregulator catalogue imply to a buyer; no vendor page was read for this entry, and no source of any kind was found that tested it. |
| Is a geroprotector like the other peptides in its family | untested | Anecdote | The compound's standing rests entirely on family resemblance. Nothing in the indexed literature measures lifespan, healthspan, or any age-related endpoint for Testagen in any species. Inheriting a claim from the catalogue a substance is sold in is not evidence, and the two available papers do not bear on it. |
The studies themselves
| Study | Design | Subjects | Quality |
|---|---|---|---|
Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF · Biochemistry. Biokhimiia · 2011
PMID 22117547
|
in_vitro / cell_culture | — HeLa cells, plus cell-free labelled deoxyribooligonucleotide and DNA-ethidium bromide systems; four peptides compared, Testagen among them | In vitro
risk of bias: high
authored by the developer |
The Inhibitory Effect and Adsorption Properties of Testagen Peptide on Copper Surfaces in Saline Environments: An Experimental and Computational Study
Dobriţescu A, Samide A, Cioateră N, Mic OC, Ionescu C, Dăbuleanu I, Tigae C, Spînu CI, Oprea B · Molecules (Basel, Switzerland) · 2025
PMID 40807317
|
in_vitro / unknown | — Copper electrodes in sodium chloride solution; no biological system is involved | Mechanistic
risk of bias: unclear
|
- No PubChem record exists under this name, so the composition gate could not independently check the sequence against a database formula.
- No study in any species has measured a reproductive, hormonal, or ageing endpoint for this compound — the endpoints its name and catalogue position imply.
- No animal study exists. No human study exists. No pharmacokinetic data exists for any route.
- No safety data of any kind exists: no adverse-event report, no toxicology, no exposure-duration record.
- Whether material sold under this name is the molecule described in the 2011 paper cannot be checked by a buyer, because there is no public chemical record for the name to check against.
- No source names the tissue this peptide is derived from or claimed to act on, which is why targetTissue and targetOrganSystem are left unresolved.
- No dose is recorded on either study here, because no full text has been read.
What people actually report
- claims about hormonal reset support
- comparison with Vilon
- requests for basic information about Testagen
What people keep asking
- What evidence is discussed for hormonal effects?
- How does Testagen compare with Vilon?
- What experiences have people had with Testagen?